[{"id":"da836897-4a66-4a1d-a97a-5a3e037619a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05431569","created_at":"2022-06-24T15:56:45.485Z","updated_at":"2024-07-02T16:36:08.342Z","phase":"Phase 2a","brief_title":"A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer","source_id_and_acronym":"NCT05431569","lead_sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","biomarkers":" EGFR • ROS1","pipe":"","alterations":" ","tags":["EGFR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e safimestomig (6MW3211)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 07/10/2022","start_date":" 07/10/2022","primary_txt":" Primary completion: 12/10/2022","primary_completion_date":" 12/10/2022","study_txt":" Completion: 09/10/2023","study_completion_date":" 09/10/2023","last_update_posted":"2022-06-24"}]